Posted by Michael Wonder on 31 Aug 2022
Schedule of Pharmaceutical Benefits - 1 September 2022
1 September 2022 - The September 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.
The September issue of the Schedule includes a number of major new/revised listings:
- Apremilast (Otezla) - restriction change
- Cabazitaxel (Cabazitaxel Accord) - new formulation
- Dapagliflozin propanediol monohydrate (Forxiga) - new indication
- Gilteritinib (Xospata) - new medicine
- Glatiramer acetate (Copaxone) - new formulation
- Niraparib tosylate monohydrate (Zejula) - new medicine
- Nusinersen sodium (Spinraza) - new indication
- Polyethylene glycol with propylene glycol (Systane) - new formulation
- Rituximab (multiple brands) - restriction change
- Selinexor (Xpovio) - new medicine
- Triglycerides - medium chain (K. Quik) - new formulation
